(R)-1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrrolidin-3-ol → HCID 59619703, 화합물
반응식
Br[C:2]1[CH:11]=[CH:10][C:9]2[N:8]=[CH:7][C:6]3[N:12]([CH3:23])[C:13](=[O:22])[N:14]([C:15]4[C:16]([CH3:21])=[N:17][N:18]([CH3:20])[CH:19]=4)[C:5]=3[C:4]=2[CH:3]=1.CC1(C)C(C)(C)OB([C:32]2[CH:33]=[CH:34][C:35]([N:38]3[CH2:42][CH2:41][C@@H:40]([OH:43])[CH2:39]3)=[N:36][CH:37]=2)O1>>[CH3:20][N:18]1[CH:19]=[C:15]([N:14]2[C:5]3[C:4]4[CH:3]=[C:2]([C:32]5[CH:37]=[N:36][C:35]([N:38]6[CH2:42][CH2:41][C@@H:40]([OH:43])[CH2:39]6)=[CH:34][CH:33]=5)[CH:11]=[CH:10][C:9]=4[N:8]=[CH:7][C:6]=3[N:12]([CH3:23])[C:13]2=[O:22])[C:16]([CH3:21])=[N:17]1참가 물질
3
실험 절차
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A) and (R)-1-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-yl]-pyrrolidin-3-ol (stage 212.1.1) to give the title compound as a white solid. (HPLC: tR 2.03 min (Method A); M+H=456 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8.90 (s, 1H), 8.25-8.22 (m, 1H), 8.12 (s, 1H), 8.05-8.01 (m, 1H), 7.87-7.83 (m, 1H), 7.57-7.53 (m, 1H), 7.43-7.41 (m, 1H), 6.55-6.51 (m, 1H), 4.95 (d, 1H), 4.42-4.36 (m, 1H), 3.92 (s, 3H), 3.56 (s, 3H), 3.54-3.43 (m, 3H), 3.37-3.31 (m, 1H), 2.08-1.86 (m, 2H), 1.96 (s, 3H))